Rohto Pharmaceutical

Rohto Pharmaceutical introduces its business and brands, which aim to contribute to global well-being through beauty and health.

Rohto Pharmaceutical expands into medical fields, continuing to develop new products and services for individual and societal health.

Rohto Pharmaceutical operates the owned media platform *Hirake, Heart! Hirake, Rohto*.

Rohto Pharmaceutical publishes a message magazine called *Taiyō Egao fufufu*, focusing on beauty and health. It introduces expert insights on issues women commonly face.

Rohto Pharmaceutical presents three business activities at Expo 2025 Osaka, Kansai, aimed at global well-being.

Rohto Pharmaceutical provides corporate information about the company.

Rohto Group introduces its management philosophy, principles, and vision as a company.

Rohto Pharmaceutical offers investor and shareholder information, including details about its investor relations (IR).

Rohto Pharmaceutical shares details about its research and development efforts and the values guiding its work.

Rohto Pharmaceutical’s official corporate website provides company information, including investor relations, social contributions, and recruitment.

Rohto Pharmaceutical describes its privacy policy.

Rohto Pharmaceutical provides investor and shareholder information, including disclaimers related to investor relations (IR).

Rohto Pharmaceutical outlines usage guidelines for its corporate website, including viewing, quoting, and copyright.

Rohto Pharmaceutical explains its social media policy.

Rohto Pharmaceutical is expanding into new markets, requiring strong in-region leadership to adapt its business model locally. The company emphasizes early appointment of senior executives in target regions to ensure successful localization. Remote management of expansions often fails, highlighting the need for on-ground expertise.

Nov 2026Mitchel Lake GroupNews article

Rohto Pharmaceutical initiates a voluntary recall of eye drops manufactured in its Vietnam facility following a U.S. FDA inspection. The FDA identified issues with manufacturing controls at the plant. The recall affects products distributed in the United States.

Aug 2026MarketScreenerNews article

Luminopia partners with ROHTO Pharmaceutical to license its FDA-cleared pediatric amblyopia treatment for Japan. The agreement marks the company’s first international licensing deal, expanding access to its lead product in a new market. ROHTO Pharmaceutical will handle commercialization and distribution in Japan.

Jun 2026PR NewswireNews article

Rohto Pharmaceutical acquires full ownership of Thann Oryza, integrating it as a subsidiary. The transaction finalizes on May 29, 2026, with financial implications under evaluation. Further details will be released as they become available.

May 2026japanir.jpNews article